REDWOOD CITY, Calif.,
Feb. 3, 2015 /PRNewswire/ -- Genomic
Health, Inc. (Nasdaq: GHDX) today announced that the company will
host a conference call and webcast on Tuesday, February 10 at 4:30 p.m. Eastern Time to discuss its fourth
quarter and year-end 2014 financial results. The call and
webcast will follow the release of the fourth quarter and year-end
financial results after market close.
Conference Call Details
To access the live conference call on February 10 at 4:30 p.m.
Eastern Time via phone, please dial (877) 303-7208 from
the United States and Canada, or +1 (224) 357-2389
internationally. The conference call ID is 75998165. Please
dial in approximately ten minutes prior to the start of the
call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of
the company's web site at http://investor.genomichealth.com.
Please connect to the web site at least 15 minutes prior to the
call to allow for any software download that may be necessary.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider
of genomic-based diagnostic tests that address both the
overtreatment and optimal treatment of early-stage cancer, one of
the greatest issues in healthcare today. The company is applying
its world-class scientific and commercial expertise and
infrastructure to lead the translation of massive amounts of
genomic data into clinically-actionable results for treatment
planning throughout the cancer patient's journey, from diagnosis to
treatment selection and monitoring. The company is based
in Redwood City, California with European
headquarters in Geneva, Switzerland. For more information, please
visit www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth, Facebook and LinkedIn.
About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions. With
half a million patients tested in more than 70 countries, the
Oncotype DX tests have redefined personalized medicine by making
genomics a critical part of cancer diagnosis and treatment. To
learn more about OncotypeDX tests,
visit: www.OncotypeDX.com,
www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits and attributes
of the company's tests to physicians and patients; the attributes
and focus of the company's product pipeline; the company's belief
that it is applying its infrastructure and expertise to lead the
translation of genomic data into clinically-actionable results; and
the applicability of clinical study results to actual outcomes.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially, and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: the risks and uncertainties associated with the
regulation of the company's tests; the results of clinical studies;
the applicability of clinical study results to actual outcomes; our
ability to develop and commercialize new tests and expand into new
markets domestically and internationally; the risk that the company
may not obtain or maintain sufficient levels of reimbursement,
domestically or abroad, for its existing tests and any future tests
it may develop; the risks of competition; unanticipated costs or
delays in research and development efforts; the company's ability
to obtain capital when needed and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the quarter ended September
30, 2014. These forward-looking statements speak only as of
the date hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks and service
marks are the property of their respective owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-announce-fourth-quarter-and-year-end-2014-financial-results-and-host-conference-call-on-tuesday-february-10-2015-300028040.html
SOURCE Genomic Health, Inc.